参附注射液对脓毒性心肌病患者的治疗效果研究  

Study on the therapeutic effect of Shenfu injection on patients with septic cardiomyopathy

作　　者：张波[1] 李显东 ZHANG Bo;LI Xian-dong(Emergency Internal Medicine Department,The Jilin Provincial People's Hospital,Changchun 130021,China)

机构地区：[1]吉林省人民医院急诊内科,130021 [2]长春市公安局朝阳分局刑事科学技术室,130000

出　　处：《中国实用医药》2025年第3期92-94,共3页China Practical Medicine

摘　　要：目的观察参附注射液对脓毒性心肌病(SCM)患者的治疗效果。方法选取82例SCM患者为研究对象,随机分为对照组和参附组,每组41例。对照组按照《中国脓毒症/脓毒性休克急诊治疗指南(2018)》进行基础治疗,参附组在对照组基础上加用参附注射液治疗。比较两组患者治疗前、治疗72 h后的平均动脉压(MAP)、心率(HR)、尿量、每搏输出量(SV)、左室射血分数(LVEF)、心肌肌钙蛋白T(cTnT)、降钙素原(PCT)、乳酸、N-末端脑钠肽前体(NT-proBNP)水平。结果治疗72 h后,两组MAP、尿量、SV、LVEF与治疗前比较显著升高,HR、PCT、乳酸、NT-proBNP与治疗前比较显著下降,差异有统计学意义(P<0.05);对照组cTnT与治疗前比较差异无统计学意义(P>0.05);参附组cTnT与治疗前比较显著下降,差异有统计学意义(P<0.05)。治疗72 h后,参附组MAP(64.4±9.2)mm Hg(1 mm Hg=0.133 kPa)、尿量(1082.2±319.2)ml/24 h、SV(64.6±9.0)ml、LVEF(47.6±3.8)%与对照组的(59.4±4.7)mm Hg、(953.3±250.9)ml/24 h、(59.2±6.5)ml、(45.5±3.9)%比较显著升高,HR(103.2±11.9)次/min、cTnT(25.9±9.9)ng/L、PCT(4.6±3.1)μg/L、乳酸(3.2±1.2)mmol/L、NT-proBNP(2347.8±1128.3)pg/ml与对照组的(108.8±7.9)次/min、(30.6±10.6)ng/L、(6.2±2.3)μg/L、(3.8±1.0)mmol/L、(2943.7±1070.3)pg/ml比较显著下降,差异有统计学意义(P<0.05)。结论参附注射液能减轻SCM患者的心肌损伤,改善血流动力学、组织灌注及心功能。Objective To observe the therapeutic effect of Shenfu injection on patients with septic cardiomyopathy(SCM).Methods A total of 82 patients with SCM were selected as study subjects and randomly divided into control group and reference group,each consisting of 41 cases.The control group received basic treatment according to the Chinese Guidelines for the Emergency Treatment of Sepsis/Septic Shock(2018),and the reference group was treated with Shenfu injection on the basis of the control group.Patients in both groups were compared in terms of mean arterial pressure(MAP),heart rate(HR),urine volume,stroke volume(SV),left ventricular ejection fraction(LVEF),cardiac troponin T(cTnT),procalcitonin(PCT),lactic acid and N-terminal brain natriuretic peptide precursor(NT-proBNP)before treatment and 72 h after treatment.Results After 72 h of treatment,MAP,urine volume,SV and LVEF in both groups were significantly increased compared with before treatment,while HR,PCT,lactic acid and NT-proBNP were significantly decreased compared with before treatment,and the difference was statistically significant(P<0.05);there was no significant difference in cTnT in the control group when compared with before treatment(P>0.05).cTnT in the reference group was significantly decreased compared with before treatment,and the difference was statistically significant(P<0.05).After 72 h of treatment,the reference group had MAP of(64.4±9.2)mm Hg(1 mm Hg=0.133 kPa),urine volume of(1082.2±319.2)ml/24 h,SV of(64.6±9.0)ml,and LVEF of(47.6±3.8)%,which were significantly increased when compared with(59.4±4.7)mm Hg,(953.3±250.9)ml/24 h,(59.2±6.5)ml,and(45.5±3.9)%in the control group;the reference group had HR of(103.2±11.9)beats/min,cTnT of(25.9±9.9)ng/L,PCT of(4.6±3.1)μg/L,lactic acid of(3.2±1.2)mmol/L,and NT-proBNP of(2347.8±1128.3)pg/ml,which were significantly decreased when compared with(108.8±7.9)beats/min,(30.6±10.6)ng/L,(6.2±2.3)μg/L,(3.8±1.0)mmol/L,and(2943.7±1070.3)pg/ml in the control group;the difference was statistically

关 键 词：脓毒性心肌病 参附注射液 心肌损伤 心功能 

分 类 号：R259[医药卫生—中西医结合]